Header cover image

U.S. Biotech Industry Analysis

UpdatedOct 31, 2024
DataAggregated Company Financials
Companies560
  • 7D0.5%
  • 3M-0.8%
  • 1Y24.7%
  • YTD3.6%

Over the last 7 days, the Biotech industry has remained flat, although notably AbbVie gained 7.2%. As for the the longer term, the industry is up 25% over the past 12 months. As for the next few years, earnings are expected to grow by 28% per annum.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 31 Oct 2024US$894.4bUS$113.6b-US$35,812,239,881.0118.6x-25x7.9x
Sat, 28 Sep 2024US$891.6bUS$113.2b-US$35,989,290,216.7121.3x-24.8x7.9x
Mon, 26 Aug 2024US$908.6bUS$113.2b-US$35,874,993,723.2123.6x-25.3x8x
Wed, 24 Jul 2024US$1.2tUS$164.5b-US$28,071,798,540.9828.8x-43x7.3x
Fri, 21 Jun 2024US$1.1tUS$164.4b-US$27,914,641,228.0727.5x-40.7x6.9x
Sun, 19 May 2024US$1.1tUS$164.6b-US$26,835,738,666.6423.9x-42.8x7x
Tue, 16 Apr 2024US$1.1tUS$164.3b-US$23,399,965,626.5221.4x-46.9x6.7x
Thu, 14 Mar 2024US$1.2tUS$167.4b-US$22,015,596,093.8918.8x-54.1x7.1x
Sat, 10 Feb 2024US$1.2tUS$169.3b-US$26,269,121,791.8719.8x-44.2x6.9x
Mon, 08 Jan 2024US$1.4tUS$204.8b-US$22,501,061,722.0020.5x-63.1x6.9x
Wed, 06 Dec 2023US$1.3tUS$204.6b-US$22,051,652,521.0019.3x-57.6x6.2x
Fri, 03 Nov 2023US$1.2tUS$206.8b-US$20,351,431,827.0017.2x-59.7x5.9x
Sun, 01 Oct 2023US$1.3tUS$207.4b-US$13,122,605,528.0017.1x-95.8x6.1x
Tue, 29 Aug 2023US$1.3tUS$207.6b-US$12,455,656,838.0017.5x-102.5x6.1x
Thu, 27 Jul 2023US$1.1tUS$186.8b-US$16,232,873,446.0014.3x-69.8x6.1x
Sat, 24 Jun 2023US$1.1tUS$186.2b-US$16,162,116,001.0013.6x-70.3x6.1x
Mon, 22 May 2023US$1.2tUS$186.0b-US$15,898,792,960.0013x-72.5x6.2x
Wed, 19 Apr 2023US$1.2tUS$198.4b-US$3,275,992,798.0013.4x-358.6x5.9x
Fri, 17 Mar 2023US$1.1tUS$199.1b-US$4,760,446,272.0013.3x-238.2x5.7x
Sun, 12 Feb 2023US$1.2tUS$202.7b-US$201,937,721.0016.4x-5723.2x5.7x
Tue, 10 Jan 2023US$1.1tUS$203.5bUS$1.7b13.8x685.5x5.6x
Thu, 08 Dec 2022US$1.2tUS$202.6bUS$1.4b14.9x839.9x5.7x
Sat, 05 Nov 2022US$1.1tUS$204.6bUS$3.6b14.2x299.5x5.3x
Mon, 03 Oct 2022US$1.0tUS$206.2bUS$5.5b14.9x187.1x4.9x
Wed, 31 Aug 2022US$1.0tUS$206.3bUS$7.3b14.4x141.1x5x
Fri, 29 Jul 2022US$1.1tUS$211.2bUS$11.2b16.4x96.6x5.1x
Sun, 26 Jun 2022US$1.1tUS$212.4bUS$11.1b15.4x95.1x4.9x
Tue, 24 May 2022US$1.0tUS$212.6bUS$11.1b14.9x90.9x4.7x
Thu, 21 Apr 2022US$1.2tUS$226.7bUS$14.8b18.1x84.2x5.5x
Sat, 19 Mar 2022US$1.3tUS$222.3bUS$10.5b19.8x123.5x5.8x
Mon, 14 Feb 2022US$1.3tUS$216.3bUS$6.0b21.8x209.6x5.8x
Wed, 12 Jan 2022US$1.4tUS$212.1bUS$2.7b24.7x501.5x6.4x
Fri, 10 Dec 2021US$1.4tUS$211.9bUS$3.0b25x464.4x6.7x
Sun, 07 Nov 2021US$1.5tUS$204.6bUS$1.1b27.3x1366x7.2x
Price to Earnings Ratio

1366x


Total Market Cap: US$1.5tTotal Earnings: US$1.1bTotal Revenue: US$204.6bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average 88.8x202220232024
Current Industry PE
  • Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 6.2x is lower than the industry's current PS ratio of 7.9x.
Past Earnings Growth
  • Total earnings for the Biotechs industry have declined over the last three years, with the industry now making a loss overall.
  • Revenues have also declined 18% per year, which is driving profits down.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market0.49%
Healthcare-1.80%
Biotech0.47%
Biotech0.47%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ABBV AbbVieUS$201.507.2%
+US$24.1b
41.4%PE67.2x
SGEN SeagenUS$228.744.5%
+US$1.8b
76.5%PS18.8x
INCY IncyteUS$73.9313.4%
+US$1.7b
36.0%PE438.5x
IBRX ImmunityBioUS$5.6463.0%
+US$1.5b
73.5%PS3003.4x
GILD Gilead SciencesUS$88.291.2%
+US$1.3b
10.1%PE104.3x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

BMRN

US$66.68

BioMarin Pharmaceutical

7D

-4.7%

1Y

-20.6%

VKTX

US$71.75

Viking Therapeutics

7D

18.8%

1Y

649.7%

TYRA

US$15.97

Tyra Biosciences

7D

-43.4%

1Y

34.5%

BGNE

US$205.99

BeiGene

7D

-6.8%

1Y

13.6%

IBRX

US$5.64

ImmunityBio

7D

63.0%

1Y

73.5%

NTLA

US$14.33

Intellia Therapeutics

7D

-28.1%

1Y

-43.8%

SMMT

US$18.65

Summit Therapeutics

7D

-6.9%

1Y

856.4%

GILD

US$88.29

Gilead Sciences

7D

1.2%

1Y

10.1%

PCVX

US$106.11

Vaxcyte

7D

-5.4%

1Y

121.1%

REGN

US$922.79

Regeneron Pharmaceuticals

7D

-2.0%

1Y

16.6%

SGEN

US$228.74

Seagen

7D

4.5%

1Y

76.5%